These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 23642576)

  • 1. The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.
    Blennow K; Zetterberg H
    Med Clin North Am; 2013 May; 97(3):369-76. PubMed ID: 23642576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.
    Bocchetta M; Galluzzi S; Kehoe PG; Aguera E; Bernabei R; Bullock R; Ceccaldi M; Dartigues JF; de Mendonça A; Didic M; Eriksdotter M; Félician O; Frölich L; Gertz HJ; Hallikainen M; Hasselbalch SG; Hausner L; Heuser I; Jessen F; Jones RW; Kurz A; Lawlor B; Lleo A; Martinez-Lage P; Mecocci P; Mehrabian S; Monsch A; Nobili F; Nordberg A; Rikkert MO; Orgogozo JM; Pasquier F; Peters O; Salmon E; Sánchez-Castellano C; Santana I; Sarazin M; Traykov L; Tsolaki M; Visser PJ; Wallin ÅK; Wilcock G; Wilkinson D; Wolf H; Yener G; Zekry D; Frisoni GB
    Alzheimers Dement; 2015 Feb; 11(2):195-206.e1. PubMed ID: 25150733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI.
    Vos S; van Rossum I; Burns L; Knol D; Scheltens P; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Handels R; L'Italien G; van der Flier W; Aalten P; Teunissen C; Barkhof F; Blennow K; Wolz R; Rueckert D; Verhey F; Visser PJ
    Neurobiol Aging; 2012 Oct; 33(10):2272-81. PubMed ID: 22264648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.
    Schaffer C; Sarad N; DeCrumpe A; Goswami D; Herrmann S; Morales J; Patel P; Osborne J
    J Lab Autom; 2015 Oct; 20(5):589-600. PubMed ID: 25424384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.
    Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM
    Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
    J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?
    Papaliagkas VT
    Recent Pat CNS Drug Discov; 2013 Apr; 8(1):70-8. PubMed ID: 23489287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease.
    Podlesniy P; Figueiro-Silva J; Llado A; Antonell A; Sanchez-Valle R; Alcolea D; Lleo A; Molinuevo JL; Serra N; Trullas R
    Ann Neurol; 2013 Nov; 74(5):655-68. PubMed ID: 23794434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
    Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
    Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease.
    Prestia A; Caroli A; van der Flier WM; Ossenkoppele R; Van Berckel B; Barkhof F; Teunissen CE; Wall AE; Carter SF; Schöll M; Choo IH; Nordberg A; Scheltens P; Frisoni GB
    Neurology; 2013 Mar; 80(11):1048-56. PubMed ID: 23390179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
    Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
    BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.
    Parnetti L; Chiasserini D
    Biomark Med; 2011 Aug; 5(4):479-84. PubMed ID: 21861669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.